Samimagham, 20 patient famotidine late treatment RCT: 33% shorter hospitalization [p=0.04] and no change in recovery [p=1] https://c19p.org/samimagham
copied to clipboard
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial
et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint)
Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2.
|
hospitalization time, 33.3% lower, relative time 0.67, p = 0.04, treatment 10, control 10.
|
|
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 5 of 10 (50.0%), control 5 of 10 (50.0%), >50% CT lung involvment.
|
|
risk of no recovery, 50.0% lower, RR 0.50, p = 0.37, treatment 3 of 10 (30.0%), control 6 of 10 (60.0%), NNT 3.3, no improvement in cough.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Samimagham et al., 27 Apr 2021, Single Blind Randomized Controlled Trial, placebo-controlled, Iran, preprint, 6 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.